Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer: Original article

F. Franchi, P. Grassi, D. Ferro, G. Pigliucci, M. De Chicchis, G. Castigliani, C. Pastore, P. Seminara

Research output: Contribution to journalArticlepeer-review

Abstract

Among a large series of cancer patients treated with a combination of chemotherapy and sessions of hyperthermia, particular attention was given to a specific group of patients with advanced cancer who refused standard, aggressive, treatment. In these cases, hyperthermia was associated to low-dose (metronomic) chemotherapy. No toxicity was reported in any of our patients, while a marginal benefit in terms of tumour progression was observed. During therapy, we could detect a coagulative perturbation that deserves careful discussion. In our opinion, this experience should be matter of debate to conclude if current response criteria (WHO/UICC and RECIST) in treating cancer patients are really suitable tools to evaluate new, and non-aggressive anticancer strategies.

Original languageEnglish
Pages (from-to)258-262
Number of pages5
JournalEuropean Journal of Cancer Care
Volume16
Issue number3
DOIs
Publication statusPublished - May 2007

Keywords

  • Chemotherapy
  • Hyperthermia
  • Palliative care
  • Tumour

ASJC Scopus subject areas

  • Nursing(all)
  • Oncology
  • Rehabilitation
  • Health Professions(all)

Fingerprint

Dive into the research topics of 'Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer: Original article'. Together they form a unique fingerprint.

Cite this